JTP 2942

structure given in first source; enhances acetylcholine release in the frontal cortex and hippocampus

Also Known As:

JTP-2942; N(alpha)-(2-methyl-4-oxocyclopentanecarbonyl)-L-histidyl-L-prolinamide; L-Prolinamide, N-((2-methyl-4-oxocyclopentyl)carbonyl)-L-histidyl-, (1S-cis)-

Networked: 5 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Katayama, Y: 1 article (05/2001)
2.	Katsumata, T: 1 article (05/2001)
3.	Muramatsu, H: 1 article (05/2001)
4.	Nakamura, H: 1 article (05/2001)
5.	Nishiyama, Y: 1 article (05/2001)
6.	Ootori, T: 1 article (05/2001)
7.	Seta, T: 1 article (05/2001)
8.	Terashi, A: 1 article (05/2001)
9.	Hojo, S: 1 article (01/2000)
10.	Nakayama, H: 1 article (01/2000)

Related Diseases

1.	Brain Ischemia (Cerebral Ischemia) 01/01/2000 - "Effect of JTP-2942, a novel thyrotropin-releasing hormone analog, on motor deficits after chronic focal cerebral ischemia in rats." 05/18/2001 - "Effect of long-term administration of JTP-2942, a novel thyrotropin-releasing hormone analogue, on neurological outcome, local cerebral blood flow and glucose utilization in a rat focal cerebral ischemia."
2.	Stroke (Strokes) 01/01/2000 - "These pharmacologic properties of JTP-2942 may be of interest for the treatment of patients with motor and neurologic deficits during the chronic or subacute phase of stroke." 01/01/2000 - "To investigate the chronic effects of a novel thyrotropin-releasing hormone analog, JTP-2942 (N(alpha)-[(1S, 2R)-2-methyl-4-oxocyclopentylcarbonyl]-L-histidyl-L-prolinamide monohydrate), on behavioral changes after stroke, the authors examined its effects on motor and neurologic deficits using a middle cerebral artery (MCA) occlusion model in rats. "
3.	Motor Neuron Disease (Primary Lateral Sclerosis) 06/26/1998 - "Our results indicate that JTP-2942 may have therapeutic potential for lower motor neuron disease or motor neuropathy."
4.	Neurologic Manifestations (Neurological Manifestations) 01/01/2000 - "These pharmacologic properties of JTP-2942 may be of interest for the treatment of patients with motor and neurologic deficits during the chronic or subacute phase of stroke." 01/01/2000 - "To investigate the chronic effects of a novel thyrotropin-releasing hormone analog, JTP-2942 (N(alpha)-[(1S, 2R)-2-methyl-4-oxocyclopentylcarbonyl]-L-histidyl-L-prolinamide monohydrate), on behavioral changes after stroke, the authors examined its effects on motor and neurologic deficits using a middle cerebral artery (MCA) occlusion model in rats. "
5.	Ischemia 05/18/2001 - "JTP-2942 (0.03 mg/kg) significantly ameliorated neurological symptoms and motor disturbance at 5 weeks after ischemia as compared with vehicle, and then after completion of drug administration, amelioration effect continued. " 05/18/2001 - "JTP-2942 (0.03 or 0.003 mg/kg) or saline (vehicle) were administered for 4 weeks after 1 week ischemia, and then the drug was withdrawn. " 05/18/2001 - "The effect of JTP-2942, a novel thyrotropin-releasing hormone analogue on neurological examination, local cerebral blood flow (l-CBF) and local cerebral glucose utilization (l-CGU) were examined when JTP-2942 was administered for 4 weeks after 1 week reperfusion following ischemia in a rat middle cerebral artery (MCA) occlusion. "

Related Drugs and Biologics

1.	Thyrotropin-Releasing Hormone (Protirelin)
2.	Thiouracil
3.	Pentobarbital (Nembutal)
4.	Glucose (Dextrose)
5.	prolinamide

Related Therapies and Procedures

1.	Muscle Denervation